Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication
Jean-Jacques Parienti, Kathleen Ragland, Frédéric Lucht, Arnaud de la Blanchardière, Sylvie Dargère, Yazdan Yazdanpanah, Jean-Jacques Dutheil, Philippe Perré, Renaud Verdon, David R Bangsberg, ESPOIR and REACH study groups, Jean-Jacques Parienti, Kathleen Ragland, Frédéric Lucht, Arnaud de la Blanchardière, Sylvie Dargère, Yazdan Yazdanpanah, Jean-Jacques Dutheil, Philippe Perré, Renaud Verdon, David R Bangsberg, ESPOIR and REACH study groups
Abstract
Consecutive missed doses may differentially impact the efficacy of antiretroviral therapy associated with the use of a nonnucleoside reverse-transcriptase inhibitor (NNRTI) and a ritonavir-boosted protease inhibitor (PI). In a cohort of 72 subjects receiving a boosted PI, average adherence to dosage was a better predictor of human immunodeficiency virus (HIV) replication than was the duration or frequency of treatment interruption. In contrast with an NNRTI, consecutive missed doses of a boosted PI did not emerge as a major risk factor for HIV replication.
Figures
Source: PubMed